Why are modeling and simulation important in cardiac safety? How are they different? In this presentation from the October 2009 DIA webinar on cardiac safety, Dr. Giri Tirucherai makes a compelling case for using both modeling and simulation in early product development to leverage data from early clinical studies to design optimal TQT studies. Learn how this approach provides a broader, more comprehensive assessment of a drug’s pro-arrhythmic potential.
Presentation December 10, 2009